发明名称 |
Compounds and methods for modulating expression of SGLT2 |
摘要 |
<p>The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are short antisense compounds comprising high-affinity nucleotide modifications useful for reducing a target RNA in vivo. Such short antisense compounds are effective at lower doses than previously described antisense compounds, allowing for a reduction in toxicity and cost of treatment. In addition, the described short antisense compounds have greater potential for oral dosing.</p> |
申请公布号 |
AU2007257094(A1) |
申请公布日期 |
2007.12.13 |
申请号 |
AU20070257094 |
申请日期 |
2007.05.07 |
申请人 |
ISIS PHARMACEUTICALS, INC. |
发明人 |
ERIC E. SWAYZE;ROBERT MCKAY;EDWARD WANCEWICZ;BRETT P. MONIA;SANJAY BHANOT;RICHARD S. GEARY;PUNIT P. SETH;ANDREW M. SIWKOWSKI |
分类号 |
A61K31/70;A61K48/00;A61P43/00;C07H21/02;C07H21/04;C12N15/113;C12Q1/68 |
主分类号 |
A61K31/70 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|